AOD-9604 in Räckelwitz — Fat Loss Peptide Research Guide
AOD-9604 research guide for Räckelwitz. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Research-Grade AOD-9604 for Räckelwitz Investigators
Most researchers looking for AOD-9604 in Räckelwitz quickly find that local retail options are essentially nonexistent. The core insight for Räckelwitz researchers: sourcing AOD-9604 comes down completely to vendor quality evaluation, not geography — and the framework for evaluating that quality is the same regardless of where you are. The key verification criteria for AOD-9604 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. What follows is a sourcing and quality evaluation guide built specifically around AOD-9604, covering everything a Räckelwitz researcher needs to evaluate quality systematically.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Räckelwitz comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can tell whether a COA is complete and credible. Mass spectrometry in the COA confirms that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. Warning signs in AOD-9604 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that do not include endotoxin results. Hold lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order AOD-9604 — ships to Räckelwitz
COA-verified · International tracking · Research grade
All use of AOD-9604 in Räckelwitz or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should comply with standard research safety practices. Lyophilised AOD-9604 should be stored frozen (−20°C) immediately upon receipt; avoid repeatedly thawing and refreezing reconstituted peptide by dividing into single-dose aliquots before freezing. Bacterial endotoxin contamination is the most serious safety risk associated with research-grade peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. The research literature on AOD-9604 should be studied thoroughly before designing any protocol — study approaches, dose levels, and measured endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
